Pentasaccharides

被引：10

作者：

Turpie, AGG ^{[1
]}

机构：

[1] Hamilton Gen Hosp, Hamilton Hlth Sci, Hamilton, ON L8L 2X2, Canada

来源：

SEMINARS IN HEMATOLOGY | 2002年 / 39卷 / 03期

关键词：

D O I：

10.1053/shem.2002.34091

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Fondaparinux sodium is the first in a new class of antithrombotic agents possessing selective inhibitory activity against factor Xa. The agent was designed and developed with the objective of overcoming the limitations of currently available therapies for the prevention and treatment of venous and arterial thromboembolic disease. Extensive data from preclinical and clinical trials demonstrate fondaparinux's favorable pharmacokinetic profile combined with promising efficacy and safety results in the prevention of venous thromboembolism following major orthopedic surgery, in the tréatment of deep venous thrombosis, and in acute coronary syndromes. Copyright 2002, Elsevier Science (USA). All rights reserved.

引用

页码：158 / 171

页数：14

共 45 条

[1] Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies [J].

Ahmad, S ;

Jeske, WP ;

Walenga, JM ;

Hoppensteadt, DA ;

Wood, JJ ;

Herbert, JM ;

Messmore, HL ;

Fareed, J .

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 1999, 5 (04) :259-266

[2] Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia [J].

Amiral, J ;

Lormeau, JC ;

MarfaingKoka, A ;

Vissac, AM ;

Wolf, M ;

BoyerNeumann, C ;

Tardy, B ;

Herbert, JM ;

Meyer, D .

BLOOD COAGULATION & FIBRINOLYSIS, 1997, 8 (02) :114-117

[3] Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. [J].

Bauer, KA ;

Eriksson, BI ;

Lassen, MR ;

Turpie, AGG .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (18) :1305-1310

[4]

BEGUIN S, 1989, THROMB HAEMOSTASIS, V61, P397

[5]

Boneu B, 1995, THROMB HAEMOSTASIS, V74, P1468

[6]

Büller HR, 2000, CIRCULATION, V102, P2726

[7] PHARMACOKINETIC AND ANTITHROMBOTIC PROPERTIES OF 2 PENTASACCHARIDES WITH HIGH-AFFINITY TO ANTITHROMBIN-III IN THE RABBIT - COMPARISON WITH CY216 [J].

CARRIE, D ;

CARANOBE, C ;

SAIVIN, S ;

HOUIN, G ;

PETITOU, M ;

LORMEAU, JC ;

VANBOECKEL, C ;

MEULEMAN, D ;

BONEU, B .

BLOOD, 1994, 84 (08) :2571-2577

[8] THE STRUCTURE OF HEPARIN OLIGOSACCHARIDE FRAGMENTS WITH HIGH ANTI-(FACTOR-XA) ACTIVITY CONTAINING THE MINIMAL ANTITHROMBIN-III-BINDING SEQUENCE - CHEMICAL AND C-13 NMR-STUDIES [J].

CASU, B ;

ORESTE, P ;

TORRI, G ;

ZOPPETTI, G ;

CHOAY, J ;

LORMEAU, JC ;

PETITOU, M ;

SINAY, P .

BIOCHEMICAL JOURNAL, 1981, 197 (03) :599-609

[9]

Choay J, 1981, Ann N Y Acad Sci, V370, P644, DOI 10.1111/j.1749-6632.1981.tb29770.x

[10] A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction - The PENTALYSE study [J].

Coussement, PK ;

Bassand, JP ;

Convens, C ;

Vrolix, M ;

Boland, J ;

Grollier, G ;

Michels, R ;

Vahanian, A ;

Vanderheyden, M ;

Rupprecht, HJ ;

Van de Werf, F .

EUROPEAN HEART JOURNAL, 2001, 22 (18) :1716-1724

← 1 2 3 4 5 →